February 6, 2017 06:27 AM EST
R&D

Bris­tol-My­ers part­ner In­nate con­cedes a PhII flop for I/O drug lir­ilum­ab in fight­ing AML

John Carroll

Editor & Founder

More than five years ago Bris­tol-My­ers Squibb her­ald­ed a $465 mil­lion deal to part­ner with In­nate Phar­ma on its nat­ur­al killer cell can­cer drug lir­ilum­ab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times